Back to News
Market Impact: 0.2
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet
Source: zacks.com
Analyst EstimatesAnalyst InsightsInvestor Sentiment & PositioningCompany Fundamentals
Foghorn Therapeutics (FHTX) has a consensus price target implying ~67% upside, though the article notes this metric is not highly predictive. The near-term bullish catalyst is an upward trend in earnings estimate revisions, which could support the stock if revisions continue. Overall, sentiment is mildly positive but framed as uncertain.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.18
Ticker Sentiment
FHTX0.25
More News
- Google brings Health Guardian to the Fitbit Air and Edge, and expands automatic activity tracking
- More than 82K rechargeable hand warmers recalled over fire risk
- Goldman Sachs, Morgan Stanley have earnings momentum and are reporting this week. There are others
- Satya Nadella went from an H-1B worker to Microsoft CEO. The Trump administration just shut that path for his employees
- Bear to bull: A double upgrade of Salesforce illustrates the folly of the 'SaaSpocalypse'
- Nvidia and AMD shares fall as new AI announcements fail to re-energize investors